

Anticipated date to be presented at LSCMMG	Provisional draft guidance consultation date	Guidance title	Specialty area	Type of guidance	Provider(s)	Capacity impact	Potential resource impact areas (costs or savings)	Financial risk level (see below for definition)	Additional information
Jan-23	NA	Kepra position statement	Neurology	Position statement	Primary and secondary		-£500,000.00	Cost saving	
Feb-23	NA	Environmental impact guidance outputs	NA	NA	LSCMMG papers and reports	NA	£0.00	Cost neutral	
Feb-23	NA	Lancashire and South Cumbria Self-Care and Access to OTC Medicines	Multiple	Guideline	Primary	TBC	TBC	TBC	TBC
Feb-23	Closed 5 th Jan 2022	Psoriasis biologics pathway	Dermatology	Clinical guideline	Secondary care	TBC	TBC	TBC	TBC
Feb-23	Dec-22	Vitamins and minerals position statement – update	Nutrition	Position statement	Primary care	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Mar-23	Jan-23	Fentanyl and buprenorphine position statement – update plus cutting patches statement	Pain	Position statement	Primary and secondary	Potentially if forces change in current practice	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Mar-23	Jan-23	Items that Should not be Routinely Prescribed in Primary Care Policy – update	Multiple	Guideline	Primary care	TBC	TBC	TBC	TBC
Mar-23	Jan-23	Cannabis based medicinal products position statement – update	CNS	Position statement	Primary and secondary	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Mar-23	Jan-23	Childhood Asthma guideline update	Respiratory	Clinical guideline	Primary care	TBC	TBC	TBC	TBC
Mar-23	Jan-23	COPD guideline update	Respiratory	Clinical guideline	Primary care	TBC	TBC	TBC	TBC

Mar-23	Jan-23	Melatonin RAG alignment	CNS	RAG review	Primary and secondary	TBC	TBC	TBC	TBC
Apr-23	Feb-23	Good prescribing in primary care guidance	Policy	Guideline	Primary care	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Apr-23	Feb-23	Trans anal irrigation position statement – update	Gastrointestinal	Clinical guideline	Primary and secondary	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Apr-23	Feb-23	Gastro biologics pathway	Gastrointestinal	Clinical guideline	Secondary care	TBC	TBC	TBC	TBC
Apr-23	Feb-23	Ketogenic diet guidance – scope	Neurology	Scope for clinical guideline	Primary and secondary	TBC	TBC	TBC	TBC
May-23	Mar-23	Stoma guidance – update	Gastrointestinal	Clinical guideline	Primary and secondary	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
May-23	Mar-23	Ophthalmology macular pathway update	Eye	Clinical guideline	Secondary care	TBC	TBC	TBC	TBC
May-23	Mar-23	Restless legs in primary care guidance – update	CNS	Clinical guideline	Primary care	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
June-23	April-23	Heart failure in diabetes guidance	Cardiovascular	Clinical guideline	Primary and secondary	TBC	TBC	TBC	TBC
June-23	April-23	Epilepsy guideline	CNS	Clinical guideline	Primary and secondary	TBC	TBC	TBC	TBC
June-23	April-23	Benzodiazepine withdrawal guideline	CNS	Clinical guideline	Primary and Secondary	TBC	TBC	TBC	TBC

TBC	TBC	DMARD SCG - Ciclosporin Leflunomide Methotrexate Mycophenolate Mofetil (Unlicensed Indications) Penicillamine Sodium Aurothiomalate Sulfasalazine.	Rheumatology	Shared care guideline	Primary and secondary	None - update of existing guidance	£0.00	Cost neutral	Do not expect update to have a significant impact on current practice
Total							-£500,000		

Financial risk level	1	2	3
	Threshold additional cost per patient per year/course Based on estimated (or actual) cost of the medicine per patient using usual maintenance dose for expected duration of treatment versus its comparator(s)	Threshold additional cost per likely population per year/course¹ Based on likely patient uptake, expected cost of the medicine, and reduced use of comparator(s)	Threshold additional cost per 100,000 people per year/course¹ Based on likely patient uptake, expected cost of the medicine, and reduced use of comparator(s)
Cost saving	Cost saving <£0	Cost saving <£0	Cost saving <£0
Cost neutral	£1 to <£700	£1 to <£1 million	£1 to <£2,000
Low	£700 to <£10,000	£1 million to <£15 million	£2,000 to <£30,000
High	≥£10,000	≥£15 million	≥£30,000